ATRC

NEUTRALEarnings

AtriCure, Inc.

2026-10-27

Price

$61.51

+0.70%

This is the 2026-10-27 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score4.5Watchlist

Signals5/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

ATRC is exhibiting high-conviction price discovery, breaking to new 52-week highs driven by a wave of analyst price target upgrades and anticipation of its November 3rd earnings report. The stock's Steady Climb and Quiet Accumulation technical signals align perfectly with recent search findings, indicating that institutions are methodically absorbing shares following strong Q2 profitability and clinical trial progress. Within the current 'Caution (Earnings)' macro regime, the remarkably tight credit spreads (0.90%) and stabilizing VIX are providing the necessary liquidity and risk-on backdrop for fundamentally strong med-tech names to sustain breakouts.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONWEAK FINISH

Key Takeaways

Actionable Thesis: ATRC is demonstrating a textbook pre-earnings accumulation phase supported by institutional buying, making it a strong momentum hold heading into its Q3 print.
Key Risk: Valuation concerns are emerging after a 110% six-month run, setting an exceptionally high bar for the upcoming earnings report to prevent a 'sell the news' reaction.
What to Watch: The $52.84 support level (20-day closing low) is the critical line-in-the-sand to maintain the current bullish market structure.

← Back to 2026-10-27 View Full ATRC History →Yahoo Finance &nearr;